- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06906341
Relacorilant en combinación con nab-paclitaxel y bevacizumab en cáncer avanzado, de ovario epitelial, peritoneal primario o de falopio
Un estudio de fase 2 de relacorilant en combinación con nab-paclitaxel y bevacizumab en cáncer avanzado, de ovario epitelial, primario peritoneal o de tubos de Falopio (Bella)
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This study is designed with the goal to add additional arms as new treatments become available. All arms will follow an independent and parallel design.
For Arms A and B, study treatment will comprise relacorilant combined with nab-paclitaxel, and bevacizumab and will begin on Cycle 1 Day 1 (C1D1). Each patient will receive relacorilant 150 mg administered orally under fed conditions, once daily for 3 consecutive days on the day before, the day of, and the day after nab-paclitaxel infusion (in Cycle 1 relacorilant is only given on 2 consecutive days, starting on C1D1), in combination with nab-paclitaxel (80 mg/m^2 intravenously [IV]) administered on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab (10 mg/kg IV once every 2 weeks [Q2W]) will be administered on Days 1 and 15 of each 28-day cycle. Study treatment for Arm C will be similar to Arm A but does not include bevacizumab. Patients will receive treatment until they reach a protocol-defined event of progressive disease (PD), experience an unmanageable toxicity, or until other treatment discontinuation criteria are met.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Corcept Therapeutics
- Número de teléfono: 650-414-2314
- Correo electrónico: corceptstudy557@corcept.com
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52074
- Reclutamiento
- 519
-
Berlin, Alemania, 10117
- Reclutamiento
- 255
-
Kempten, Alemania, 87439
- Reclutamiento
- 520
-
-
-
-
-
Brussels, Bélgica, 1200
- Reclutamiento
- 109
-
Charleroi, Bélgica, 6000
- Reclutamiento
- 326
-
Hasselt, Bélgica, 3500
- Reclutamiento
- 325
-
Leuven, Bélgica, 3000
- Reclutamiento
- 108
-
-
Belgium
-
Aalst, Belgium, Bélgica, 9300
- Reclutamiento
- 328
-
-
-
-
Gangnam-gu
-
Seoul, Gangnam-gu, Corea del Sur, 06351
- Reclutamiento
- 396
-
-
Goyang-si
-
Gyeonggi-do, Goyang-si, Corea del Sur, 10408
- Reclutamiento
- 397
-
-
Jongno-gu
-
Seoul, Jongno-gu, Corea del Sur, 03080
- Reclutamiento
- 399
-
-
Seocho-gu
-
Seoul, Seocho-gu, Corea del Sur, 06591
- Reclutamiento
- 523
-
-
Seodaemun-gu
-
Seoul, Seodaemun-gu, Corea del Sur, 03722
- Reclutamiento
- 398
-
-
Songpa-gu
-
Seoul, Songpa-gu, Corea del Sur, 05505
- Reclutamiento
- 403
-
-
-
-
-
Badalona, España, 08916
- Reclutamiento
- 349
-
Barcelona, España, 08035
- Reclutamiento
- 115
-
Madrid, España, 28034
- Reclutamiento
- 114
-
Valencia, España, 46026
- Reclutamiento
- 330
-
Valencia, España, 46010
- Reclutamiento
- 558
-
-
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- Reclutamiento
- 004
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Reclutamiento
- 150
-
San Francisco, California, Estados Unidos, 94109
- Reclutamiento
- 278
-
San Francisco, California, Estados Unidos, 94143
- Reclutamiento
- 014
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- 032
-
-
Florida
-
Fort Myers, Florida, Estados Unidos, 33901
- Reclutamiento
- 544
-
Miami Beach, Florida, Estados Unidos, 33140
- Reclutamiento
- 335
-
West Palm Beach, Florida, Estados Unidos, 33041
- Reclutamiento
- 543
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- 001
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55404
- Reclutamiento
- 518
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- Reclutamiento
- 334
-
St Louis, Missouri, Estados Unidos, 63110
- Reclutamiento
- 521
-
-
New Mexico
-
Albuquerque, New Mexico, Estados Unidos, 97102
- Reclutamiento
- 292
-
-
Ohio
-
Centerville, Ohio, Estados Unidos, 45459
- Reclutamiento
- 304
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401
- Reclutamiento
- 517
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- Reclutamiento
- 127
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- 522
-
Norfolk, Virginia, Estados Unidos, 23502
- Reclutamiento
- 300
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Reclutamiento
- 121
-
-
-
-
-
Lille, Francia, 59000
- Reclutamiento
- 306
-
Nancy, Francia, 54100
- Reclutamiento
- 307
-
Nice, Francia, 06100
- Reclutamiento
- 310
-
Pierre-Bénite, Francia, 69495
- Reclutamiento
- 324
-
Plérin, Francia, 22190
- Reclutamiento
- 323
-
Toulouse, Francia, 31059
- Reclutamiento
- 308
-
-
-
-
-
Catania, Italia, 95126
- Reclutamiento
- 321
-
Milan, Italia, 20141
- Reclutamiento
- 122
-
Milan, Italia, 20159
- Reclutamiento
- 516
-
Pavia, Italia, 27100
- Reclutamiento
- 295
-
Rome, Italia, 00168
- Reclutamiento
- 124
-
Torino, Italia, 10128
- Reclutamiento
- 293
-
Treviso, Italia, 31100
- Reclutamiento
- 319
-
-
-
-
-
Gdynia, Polonia, 81-519
- Reclutamiento
- 341
-
Siedlce, Polonia, 08-MO
- Reclutamiento
- 329
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
Arms A and B
- Histologic diagnosis of epithelial ovarian, primary peritoneal, or fallopian-tube carcinoma
- Arm A Only: Platinum-resistant disease
- Arm B Only: Platinum-sensitive disease who had progression while receiving treatment with a poly(ADP-ribose) polymerase (PARP) inhibitor
- Life expectancy of ≥3 months
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Able to swallow and retain oral medication
- 1 to 3 lines of prior systemic anticancer therapy
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Arm C
- Stage III or IV, recurrent, or metastatic endometrial cancer
- Life expectancy of ≥3 months
- ECOG performance status of 0 or 1
- Able to swallow and retain oral medication
- Prior treatment with a platinum agent and an approved anti-Programmed Cell Death Ligand 1 (PD[L]1) antibody
- 1 to 2 lines of prior systemic anticancer therapy for endometrial cancer
- Must consent to provide an available formalin-fixed paraffin-embedded (FFPE) tumor tissue block or recently cut sections
- Adequate organ function
- Negative pregnancy test for patients of childbearing potential
Exclusion Criteria:
Arm A and B
- Arm A Only: Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Hypertension: ≥150 mm Hg systolic or ≥100 mm Hg diastolic
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- Untreated or symptomatic central nervous system metastases
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
Arm C
- Has progressed while receiving weekly paclitaxel or nab-paclitaxel
- Prior enrollment in a clinical trial of relacorilant
- Prior anticancer therapy related toxicities not resolved to grade ≤1
- Any surgery within 4 weeks prior to enrollment
- Wide-field radiation to more than 25% of marrow-bearing areas
- Medical conditions requiring chronic or frequent treatment with corticosteroids
- Concurrent treatment with mifepristone or other glucocorticoid receptor modulators
- Peripheral neuropathy from any cause >Grade 1
- Uncontrolled condition(s) which, may confound the results of the trial or interfere with the patient's safety or participation
- Bowel obstruction ≤12 weeks prior to study entry
- Ascites or pleural effusions requiring therapeutic paracentesis
- History of other malignancy within 3 years prior to enrollment
- Has received a live vaccine within 30 days prior to the study start date
- Patients with central nervous system metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Arm A: Relacorilant in Combination with Nab-paclitaxel and Bevacizumab
In Arm A, patients with platinum-resistant ovarian cancer will receive the combination of relacorilant with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Otros nombres:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimental: Arm B: Relacorilant in Combination with Nab-Paclitaxel and Bevacizumab
In Arm B, patients with platinum-sensitive ovarian cancer who have progressed while receiving treatment with a polymerase inhibitor will receive relacorilant in combination with nab-paclitaxel and bevacizumab. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Otros nombres:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. Bevacizumab is administered as IV infusion on Days 1 and 15. |
|
Experimental: Arm C: Relacorilant in Combination with Nab-Paclitaxel
In Arm C, patients with previously-treated advanced, recurrent, or metastatic endometrial cancer will receive relacorilant in combination with nab-paclitaxel. |
Relacorilant is administered under fed conditions as capsules for oral dosing on the day before, the day of, and the day after nab-paclitaxel infusion.
Otros nombres:
Nab-paclitaxel is administered as IV infusion on Days 1, 8, and 15 of each 28-day cycle. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Date of first dose until PD or death, up to 18 months
|
To evaluate PFS as the time from enrollment until first documented progressive disease (PD) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by the Investigator, or death due to any cause, whichever occurs first. |
Date of first dose until PD or death, up to 18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de pacientes con uno o más eventos adversos
Periodo de tiempo: Fecha de la primera dosis hasta 30 días después de la última dosis
|
Fecha de la primera dosis hasta 30 días después de la última dosis
|
|
|
Objective Response Rate (ORR)
Periodo de tiempo: Date of first dose until PD or death, up to 18 months
|
To evaluate the proportion of patients with measurable disease at Baseline who attain complete response (CR) or partial response (PR) by RECIST version 1.1. |
Date of first dose until PD or death, up to 18 months
|
|
Best Overall Response Rate (BOR)
Periodo de tiempo: Date of first dose until PD or death, up to 18 months
|
To evaluate the BOR by RECIST version 1.1 recorded from the date of enrollment until PD or death. |
Date of first dose until PD or death, up to 18 months
|
|
Duration of Response (DOR)
Periodo de tiempo: Time of first objective response until PD or death, up to 18 months
|
To evaluate DOR as the time from the first CR or PR to first objectively documented PD or death, whichever comes first. |
Time of first objective response until PD or death, up to 18 months
|
|
Clinical Benefit Rate (CBR)
Periodo de tiempo: Week 24
|
To evaluate CBR as the proportion of patients who attain CR, PR, or stable disease (SD) at Week 24 as per RECIST version 1.1. |
Week 24
|
|
Overall Survival (OS)
Periodo de tiempo: Date of first dose up to 6, 12, and 18 months
|
To evaluate the probability of OS survival at 6, 12, and 18 months. |
Date of first dose up to 6, 12, and 18 months
|
|
Area under the plasma concentration-time curve (AUC) of relacorilant
Periodo de tiempo: On Cycle 1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 1 Day 8 (each cycle is 28 days)
|
|
Maximum plasma concentration (Cmax) of relacorilant
Periodo de tiempo: On Cycle1 Day 8 (each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle1 Day 8 (each cycle is 28 days)
|
|
Trough plasma concentrations (Cmin) of relacorilant
Periodo de tiempo: On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
To estimate exposure of relacorilant. This outcome applies to Arms B and C only. |
On Cycle 2 Day 8 through the last cycle (up to 12 cycles, each cycle is 28 days)
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Danny Nguyen, MD, Corcept Therapeutics
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Neoplasias
- Bevacizumab
- Neoplasias Ováricas
- Paclitaxel
- Relajante
- Nab-paclitaxel
- Ovárico
- Neoplasias por sitio
- Endometrial
- Alto grado
- Enfermedades Ováricas
- Neoplasias Genitales Femeninas
- Neoplasias Peritoneales
- Neoplasias de las trompas de Falopio
- Resistente al platino
- Neoplasia Endometrial
- Enfermedades de las trompas de Falopio
- Paclitaxel unido a albúmina
- Cáncer de trompa de Falopio peritoneal o avanzado
- Bella
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Enfermedades del sistema endocrino
- Neoplasias urogenitales
- Enfermedades urogenitales femeninas
- Enfermedades urogenitales femeninas y complicaciones del embarazo
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades uterinas
- Enfermedades Genitales Femeninas
- Neoplasias de glándulas endocrinas
- Enfermedades anexiales
- Trastornos gonadales
- Neoplasias Uterinas
- Enfermedades Peritoneales
- Neoplasias Abdominales
- Neoplasias
- Neoplasias Ováricas
- Neoplasias Endometriales
- Neoplasias Genitales Femeninas
- Neoplasias Peritoneales
- Neoplasias de las trompas de Falopio
- Neoplasias por sitio
- Enfermedades Ováricas
- Enfermedades de las trompas de Falopio
- Aminoácidos, péptidos y proteínas
- Proteínas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Bevacizumab
- Paclitaxel de 130 nm en albúmina
- relacorilante
Otros números de identificación del estudio
- CORT125134-557
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .